Plozasiran + Placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Severe Hypertriglyceridemia
Conditions
Severe Hypertriglyceridemia
Trial Timeline
Apr 24, 2025 → Jun 1, 2029
NCT ID
NCT06880770About Plozasiran + Placebo
Plozasiran + Placebo is a phase 3 stage product being developed by Arrowhead Pharmaceuticals for Severe Hypertriglyceridemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06880770. Target conditions include Severe Hypertriglyceridemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06880770 | Phase 3 | Recruiting |
| NCT05089084 | Phase 3 | Active |
Competing Products
20 competing products in Severe Hypertriglyceridemia